Alkynl and azido-substituted 4-anilinoquinazolines

Details Alkynl and azido-substituted 4-anilinoquinazolines Alkynl and azido-substituted 4-anilinoquinazolines

2008-02-27

2009-12-29

Balasubramanian, Venkataraman (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S293000, C544S283000

Reissue Patent

active

RE041065

ABSTRACT:
The invention relates to compounds of the formulaand to pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, n and m are as defined herein. The compounds of formula I are useful in the treatment of hyperproliferative diseases, such as cancer. The invention further relates to processes of making the compounds of formula I and to methods of using such compounds in the treatment of hyperproliferative diseases.

REFERENCES:
patent: 4138590 (1979-02-01), Kao
patent: 5214144 (1993-05-01), Tai et al.
patent: 5256781 (1993-10-01), Primeau et al.
patent: 5427766 (1995-06-01), Dowd
patent: 5436233 (1995-07-01), Lee et al.
patent: 5439895 (1995-08-01), Lee et al.
patent: 5457105 (1995-10-01), Barker
patent: 5475001 (1995-12-01), Barker
patent: 5616582 (1997-04-01), Barker
patent: 5654307 (1997-08-01), Bridges et al.
patent: 5736534 (1998-04-01), Arnold
patent: 6900221 (2005-05-01), Norris et al.
patent: 2086968 (1998-06-01), None
patent: 2086968 (1998-06-01), None
patent: 2936705 (1980-03-01), None
patent: 0 477 700 (1992-04-01), None
patent: 520722 (1992-12-01), None
patent: 0 520 722 B1 (1992-12-01), None
patent: 0 566 226 (1993-10-01), None
patent: 566226 (1993-10-01), None
patent: 602851 (1994-06-01), None
patent: 0 602 851 (1994-06-01), None
patent: 635498 (1995-01-01), None
patent: 0 635 498 (1995-01-01), None
patent: 0 635 507 (1995-01-01), None
patent: 466233 (1975-04-01), None
patent: WO 92/20642 (1992-11-01), None
patent: 92/20642 (1992-11-01), None
patent: WO 93/04047 (1993-03-01), None
patent: 1995/03283 (1995-02-01), None
patent: WO 95/15758 (1995-06-01), None
patent: 95/15758 (1995-06-01), None
patent: 1996/15118 (1996-05-01), None
patent: 1996/28430 (1996-09-01), None
patent: 1997/32856 (1997-09-01), None
patent: 1998/13354 (1998-04-01), None
patent: 2004/072049 (2004-08-01), None
patent: 1997/30035 (2007-08-01), None
Golub et al., Science, 286, 531-537, 1999.
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed”, Marcel Dekker, New York. 1996, pp. 451 and 596.
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition, vol. 1, 1004-1010, 1996.
Traxler et al. Ex. Opin. Ther. Patents 7(6):571-588, 1997.
Freshney et al., Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p4.
Dermer et al., Bio/Technology, 1994, 12:320.
Powell et al., British Journal of Dermatology, 141: 802-810, 1999.
Cohen et al., Current Opinion in Chemical Biology, 3, 459-465, 1999.
Opposition filed by Natco Pharma on Apr. 5, 2007, in respect of Indian Patent Application No. 537 DEL/96.
In the High Court of Delhi at New Delhi, C.S. (O.S.) No. 89 of 2008 in re:F. Hoffman LA Roche Ltd. &Anr . . .Vs.CIPLA, Counterclaim of the Defendant Under 64 of the Patents Act for Revocation of Patent No. 196774 Titled “A novel [6,7 -bis (2-methoxyethoxy)quinazolin-4-yl]-(3-ethynylphenyl) amine hydrochloride, ” Jan. 21, 2008.
In the High Court of Delhi at New Delhi, C.S. (O.S.) No. 89 of 2008 in re:F. Hoffman LA Roche Ltd. &AnrVs.CIPLA, Written Statement on Behalf of the Defendant to the Injunction Application, Jan. 21, 2008.
Before the Registrar of Patents and Designs in Jerusalem in re:Teva Pharmaceutical IndustriesVs.OSI Pharmaceuticals, Inc., Opponent's Statement of Arguments and Appendices, Aug. 5, 2007.
Fry, D. W. et al., “A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase,” Science, Aug. 19, 1994, 265, 1093-1095.
Thornber, C. W., “Isosterism and Molecular Modification in Drug Design,” 1979, Chem. Soc. Rev., 8, 563-580.
In the High Court of Delhi, C.S. (O.S.) No. 89 of 2008 in re:F. Hoffman LA Roche Ltd. &AnrVs.CIPLA, Written Arguments on Behalf of the Defendants, Feb. 5, 2008.
In the United States Patent and Trademark Office, Application for Extension of Patent Term Under 35 U.S.C. 156, in re: U.S. Patent No. 5,747,498, dated Jan. 13, 2005, 22 pages.
Reply Statement in support by the Applicant for Indian Patent Application No. 537/DEL/96 made by Pfizer Products Inc. and OSI Pharmaceuticals Inc., with enclosures, Jun. 4, 2007.
Decision on Pre-Grant Opposition in re. Matter of Indian Patent Application No. 537/Del/1996, in the name of Pfizer Products Inc, and OSI Pharmaceuticals Inc., Jul. 4, 2007.
Armarego, W.L.F., “Fused Pyrimidines”, Interscience Publishers, 1967, Part 1, Chapters 4, 5, pp. 69 thru 269.
Barker, A.J., “Quinazoline Tyrosine Kinase-Inhibiting Anticancer Agents”, 1993, DialogWeb, Abstract, 2 pages.
Botros, S. et al., “Synthesis of Certain Nitroquinazoline Structurally Related to Some Chemotherapeutic Agents”, Egypt. J. Pharm. Sci., 1972, 13(1), 1-21.
LeMahieu, R.A. et al., “(e)-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acids, a New Series of Antiallergy Agents”, J. Med. Chem., 1983, 26(3), 420-425.
Sun, C. et al., “Studies on Drugs for Coronary Diseases. II. Synthesis of Compounds Related to Changrolin, a New Antiarrhythmic Agent”, 1981, DialogWeb, 2 pages Abstract, 565-570 (publication believed to be abstracted also enclosed).
Chemical Abstracts, American Chemical Society, Abstract 98:107246, 1983, 98(13), 4 pages.
Wiley Rein letter dated Feb. 23, 2009, and Detailed Legal and Factual Basis for Mylan's Paragraph IV Patent Certification regarding U.S. Patent Nos. 5,747,498, 6,900,221 and 7,087,61.
Hansch, C. et al., “Aromatic constituent constants for structure-activity corellations,” J. Med. Chem., 1973 16(11), 1207-1216.
Pollack, V.A. et al., “Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774: Dynamics of receptor inhibition In Situ and antitumor effects in athymic mice,” J. Pharmacol. Exp Ther., 1999, 291, 739-748.
Moody, T.W., “Peptides and Growth Factors in Non-Small Cell Lung Cancer,” Peptides, 1996, 17(3), 545-555.
Hickish, T.F. et al., “Clinical benefit from palliative chemotheraphy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors,” British Journal of Cancer, 1998, 78(1), 28-33.
Jong Ho Park et al., “Postoperative Adjuvant Therapy for Stage II Non-Small-Cell Lung Cancer,” Ann Thorac Surg, 1999, 68, 1821-1826.
The Merck Manual of Diagnosis and Therapy, 1999, Seventeenth Edition, Beers, M.H. et al., (eds.), Published by Merck Research Laboratories, Whitehouse Station, NJ., pp. 988-995.
Mattson, K., “Docetaxel (Taxotere®) in the neo-adjuvant setting in non-small-cell lung cancer,” Annals of Oncology, 1999, 10(Suppl. 5), S69-S72.
Batra, S.K. et al., “Epdiermal Growth Factor Ligand-independent, Unregulated, Cell-transforming Potential of a Naturally Occurring Human Mutant EGFRvlll Gene,” Cell Growth & Differentiation, Oct. 1995, 6, 1251-1259.
Pollack, V.A. et al., “Therapy of human carcinoma in athymic mice by inhibition of EGF receptor-mediated signal transduction with CP-358774: Dynamics of receptor inhibition and anti-tumor effects,” Proc. American Association for Cancer Research, Mar. 1997, vol. 38, p. 633, Abstract No. 4249.
In the High Court of Delhi at New Delhi, in Re.:F. Hoffman LA Roche Ltd&Anr.VersusCIPLA Ltd., Written Submissions on Behalf of the Respondent, CIPLA Limited, and Annexures A-H, Aug. 27, 2008.
Structural Similarities with the Closest Prior Art—Annex B to CIPLA's written arguments dated Aug. 27, 2008.
In the United States District Court for the District of Delaware, Civ. A. No. 09-185, In Re.:OSI Pharmaceuticals, Inc., Pfizer Inc., and Genentech, Inc.v.Teva Pharmaceuticals USA, Inc.: Complaint for patent infringement and related documents, Mar. 19, 2009, 92 pages.
In the United States District Court for the District of Delaware, Civ. A. No. 09-186, In Re.:OSI Pharmsceuticals, Inc., Pfizer Inc., and Genentech, Inc.v.Mylan Pharmaceuticals, Inc.: Complaint for patent infringement and related

Affiliated with

Also associated with

Rating

Alkynl and azido-substituted 4-anilinoquinazolines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Alkynl and azido-substituted 4-anilinoquinazolines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alkynl and azido-substituted 4-anilinoquinazolines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4082519